Minimal Residual Disease in Acute Myeloid Leukemia: Old and New Concepts.
Chea M, Rigolot L, Canali A, Vergez F.
Int J Mol Sci. 2024 Feb 10;25(4):2150. doi: 10.3390/ijms25042150.
Minimal residual disease as a target for liquid biopsy in patients with solid tumours.
Pantel K, Alix-Panabières C.
Nat Rev Clin Oncol. 2025 Jan;22(1):65-77. doi: 10.1038/s41571-024-00967-y. Epub 2024 Nov 28.
[Minimal residual disease in AML].
Taga T.
Rinsho Ketsueki. 2020;61(4):343-349. doi: 10.11406/rinketsu.61.343.
Sustained minimal residual disease in myeloma.
Bianchi G.
Blood. 2022 Jan 27;139(4):469-471. doi: 10.1182/blood.2021013199.
Minimal Residual Disease-Adapted Therapy in Multiple Myeloma: Current Evidence and Opinions.
Meseha M, Hoffman J, Kazandjian D, Landgren O, Diamond B.
Curr Oncol Rep. 2024 Jun;26(6):679-690. doi: 10.1007/s11912-024-01537-2. Epub 2024 Apr 27.
Minimal Residual Disease in Multiple Myeloma: Ready for Prime Time?
Mina R, Bonello F, Oliva S.
Cancer J. 2021 May-Jun 01;27(3):247-255. doi: 10.1097/PPO.0000000000000519.
Minimal Residual Disease Monitoring with Next-Generation Sequencing Methodologies in Hematological Malignancies.
Sánchez R, Ayala R, Martínez-López J.
Int J Mol Sci. 2019 Jun 10;20(11):2832. doi: 10.3390/ijms20112832.
Role of Minimal Residual Disease Testing in Acute Myeloid Leukemia.
Chen X, Cherian S.
Clin Lab Med. 2021 Sep;41(3):467-483. doi: 10.1016/j.cll.2021.03.017. Epub 2021 Jul 2.
Monitoring minimal residual disease in the bone marrow using next generation sequencing.
Rustad EH, Boyle EM.
Best Pract Res Clin Haematol. 2020 Mar;33(1):101149. doi: 10.1016/j.beha.2020.101149. Epub 2020 Jan 17.
Minimal residual disease in systemic light chain amyloidosis: a systematic review and meta-analysis.
Li X, Yu Y, Yu H, Chen M, Zhang X, Wu Y.
J Cancer Res Clin Oncol. 2024 Apr 15;150(4):193. doi: 10.1007/s00432-024-05733-2.
